TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
The Importance of Small Wins
The implications of making those indication decisions are probably pretty serious for an emerging biotech. Some indications are considerably more expensive to chase than others, right? Yeah. And I think it also depends on what your technology is,. There's cold tumors, and then there's hot tumors, right? Certain lung cancers, melanoma, they're considered hot tumors. They may be easier to target depending on what your treatment is.
Transcript
Play full episode
